중추신경계 내 SIRT1의 역할 = The Role of SIRT1 in Central Nervous System

다국어 초록 (Multilingual Abstract)

Silent mating type information regulation 2 homolog 1 (SIRT1) is a nicotinamide adenosine dinucleotide (NAD+)-dependent class III histone deacetylase and is distributed in central nervous system and peripheral tissue. SIRT1 interacts with various transcription factors and cofactors by histone deacetylation and is involved in the modulation of food intake, energy metabolism, circadian rhythms, learning and memory, neurogenesis and neuroprotection. Increased or decreased SIRT1 activity or levels by pharmacological treatment or in genetic animal models have demonstrated its function and role in Central Nervous System and peripheral tissue. Recent study suggests that dysregulation of SIRT1 may be involved in anxiety or depression, but relatively little is known about the involvement of SIRT1 in anxiety or depression. Therefore, through unraveling the functional role of SIRT1 in food intake, energy metabolism, learning and memory as well as neuropsychiatric disease, studies on SIRT1 can shed light on the new drug development in treating neurodegenerative disease, metabolic disorder and neuropsychiatric disorder.

국문 초록 (Abstract)

포유류에서 SIRT1은 NAD+ 농도에 의존하는 탈아세틸화효소로서 중추신경계 및 말초 조직에 분포되어 있다. SIRT1은 히스톤 뿐 아니라 다양한 전사 인자 및 보조인자(cofactor)들을 탈아세틸화 시킴으로 조절하여 각 생체기관에 다양한역할을 수행하는 것으로 알려져 있다. 특히 중추신경계에 존재하는 SIRT1은 식이와 에너지 대사조절, 하루주기리듬, 학습과 기억, 신경발생, 신경보호효과 등에 관여하고 있다. 반면 SIRT1의 기능 이상시 불안이나 우울증과 같은 신경정신질환의 발병과 관련 있을 것으로 추정되고 있으나 그에 대한연구는 그리 많지 않은 실정이다. 따라서 식이나 에너지 대사조절, 학습과 기억 및 신경정신질환에서의 SIRT1의 역할 규명을 통하여 다양한 중추신경계 질환에 대한 신약개발의 가능성을 제시할 수 있으리라 생각된다.

참고문헌 (Reference)

• 1 Tippmann F, "Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin" 23 : 1643-1654, 2009
• 2 Luo JL, "UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin" 61 : 8158-8163, 2001
• 3 Andrews ZB, "UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals" 454 : 846-851, 2008
• 4 Imai S, "Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase" 403 : 795-800, 2000
• 5 Hisahara S, "Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRT1 (Sir2alpha)" 98 : 200-204, 2005
• 6 Chen D, "Tissue-specific regulation of SIRT1 by calorie restriction" 22 : 1753-1757, 2008
• 7 Donmez G, "The neurobiology of sirtuins and their role in neurodegeneration" 33 : 494-501, 2012
• 8 Green CB, "The meter of metabolism" 134 : 728-742, 2008
• 9 McBurney MW, "The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis" 23 : 38-54, 2003
• 10 Browne SE, "The energetics of Huntington’s disease" 29 : 531-546, 2004
• 11 Zhang J, "The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation" 282 : 34356-34364, 2007
• 12 Hardy J, "The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics" 297 : 353-356, 2002
• 13 Lemieux ME, "The Sirt1 deacetylase modulates the insulin-like growth factor signaling pathway in mammals" 126 : 1097-1105, 2005
• 14 Nakahata Y, "The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control" 134 : 329-340, 2008
• 15 Cantó C, "Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?" 64 : 166-187, 2012
• 16 Staubli U, "Stable hippocampal long-term potentiation elicited by ‘theta’ pattern stimulation" 435 : 227-234, 1987
• 17 Julien C, "Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease" 68 : 48-58, 2009
• 18 Kakefuda K, "Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection" 387 : 784-788, 2009
• 19 Schug TT, "Sirtuin 1 in lipid metabolism and obesity" 43 : 198-211, 2011
• 20 Pfluger PT, "Sirt1 protects against high-fat diet-induced metabolic damage" 105 : 9793-9798, 2008
• 21 Picard F, "Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma" 429 : 771-776, 2004
• 22 Jeong H, "Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway" 18 : 159-165, 2011
• 23 Prozorovski T, "Sirt1 contributes critically to the redox-depen dent fate of neural progenitors" 10 : 385-394, 2008
• 24 Li Y, "SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons" 8 : 38-48, 2008
• 25 Banks AS, "SirT1 gain of function increases energy efficiency and prevents diabetes in mice" 8 : 333-341, 2008
• 26 Endres K, "Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases" 272 : 5808-5820, 2005
• 27 Bordone L, "SIRT1 transgenic mice show phenotypes resembling calorie restriction" 6 : 759-767, 2007
• 28 Donmez G, "SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10" 142 : 320-332, 2010
• 29 Asher G, "SIRT1 regulates circadian clock gene expression through PER2 deacetylation" 134 : 317-328, 2008
• 30 Chen J, "SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling" 280 : 40364-40374, 2005
• 31 Satoh A, "SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus" 30 : 10220-10232, 2010
• 32 Michán S, "SIRT1 is essential for normal cognitive function and synaptic plasticity" 30 : 9695-9707, 2010
• 33 Kishi T, "SIRT1 gene, schizophrenia and bipolar disorder in the Japanese population: an association study" 10 : 257-263, 2011
• 34 Kim D, "SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis" 26 : 3169-3179, 2007
• 35 Ramadori G, "SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity" 12 : 78-87, 2010
• 36 Libert S, "SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive" 147 : 1459-1472, 2011
• 37 Mattson MP, "Roles for NF-kappaB in nerve cell survival, plasticity, and disease" 13 : 852-860, 2006
• 38 Della-Morte D, "Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway" 159 : 993-1002, 2009
• 39 Raval AP, "Resveratrol mimics ischemic preconditioning in the brain" 26 : 1141-1147, 2006
• 40 Kabe Y, "Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus" 7 : 395-403, 2005
• 41 Joseph SB, "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors" 9 : 213-219, 2003
• 42 Zhang F, "Protective effects and mechanisms of sirtuins in the nervous system" 95 : 373-395, 2011
• 43 Larson J, "Patterned stimulation at the theta frequency is optimal for the induction of hippocampal long-term potentiation" 368 : 347-350, 1986
• 44 Gan L, "Paths of convergence: sirtuins in aging and neurodegeneration" 58 : 10-14, 2008
• 45 Dauer W, "Parkinson’s disease: mechanisms and models" 39 : 889-909, 2003
• 46 Wareski P, "PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons" 284 : 21379-21385, 2009
• 47 Liu D, "Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons" 11 : 28-42, 2009
• 48 Cohen DE, "Neuronal SIRT1 regulates endocrine and behavioral responses to calorie restriction" 23 : 2812-2817, 2009
• 49 Libert S, "Neurogenesis directed by Sirt1" 10 : 373-374, 2008
• 50 Lin MT, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases" 443 : 787-795, 2006
• 51 Holback S, "Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells" 95 : 1059-1068, 2005
• 52 Chen D, "Increase in activity during calorie restriction requires Sirt1" 310 : 1641-, 2005
• 53 Cakir I, "Hypothalamic Sirt1 regulates food intake in a rodent model system" 4 : e8322-, 2009
• 54 Renthal W, "Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli" 56 : 517-529, 2007
• 55 Accili D, "FoxOs at the crossroads of cellular metabolism, differentiation, and transformation" 117 : 421-426, 2004
• 56 Xiong S, "FoxO1 mediates an autofeedback loop regulating SIRT1 expression" 286 : 5289-5299, 2011
• 57 Kitamura T, "Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake" 12 : 534-540, 2006
• 58 Jiang Y, "Epigenetics in the nervous system" 28 : 11753-11759, 2008
• 59 Feng J, "Epigenetic regulation of neural gene expression and neuronal function" 61 (61): 58R-63R, 2007
• 60 Tsankova N, "Epigenetic regulation in psychiatric disorders" 8 : 355-367, 2007
• 61 Cheng HL, "Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice" 100 : 10794-10799, 2003
• 62 Schmitt U, "Detection of behavioral alterations and learning deficits in mice lacking synaptophysin" 162 : 234-243, 2009
• 63 Grozinger CM, "Deacetylase enzymes: biological functions and the use of small-molecule inhibitors" 9 : 3-16, 2002
• 64 Imai S, "Clocks in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging" 1804 : 1584-1590, 2010
• 65 Boden MJ, "Circadian rhythms and reproduction" 132 : 379-392, 2006
• 66 Kim K, "Circadian rhythm of adrenal glucocorticoid: its regulation and physiological relevance" 49 : 43-77, 2010
• 67 Doi M, "Circadian regulator CLOCK is a histone acetyltransferase" 125 : 497-508, 2006
• 68 Nakahata Y, "Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1" 324 : 654-657, 2009
• 69 Ramsey KM, "Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis" 324 : 651-654, 2009
• 70 Trejo JL, "Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects" 12 : 1118-1128, 2007
• 71 Qin W, "Calorie restriction attenuates Alzheimer’s disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus)" 10 : 417-422, 2006
• 72 Patel NV, "Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models" 26 : 995-1000, 2005
• 73 Hirayama J, "CLOCK-mediated acetylation of BMAL1 controls circadian function" 450 : 1086-1090, 2007
• 74 Nguyen PV, "Brief theta-burst stimulation induces a transcription-dependent late phase of LTP requiring cAMP in area CA1 of the mouse hippocampus" 4 : 230-243, 1997
• 75 Ramadori G, "Brain SIRT1: anatomical distribution and regulation by energy availability" 28 : 9989-9996, 2008
• 76 Trifilieff P, "Biphasic ERK1/2 activation in both the hippocampus and amygdala may reveal a system consolidation of contextual fear memory" 88 : 424-434, 2007
• 77 Zelcer N, "Attenuation of neuroinflammation and Alzheimer’s disease pathology by liver x receptors" 104 : 10601-10606, 2007
• 78 Baur JA, "Are sirtuins viable targets for improving healthspan and lifespan?" 11 : 443-461, 2012
• 79 Covington HE 3rd, "Antidepressant actions of histone deacetylase inhibitors" 29 : 11451-11460, 2009
• 80 Abe N, "Altered sirtuin deacetylase gene expression in patients with a mood disorder" 45 : 1106-1112, 2011
• 81 Dietrich MO, "Agrp neurons mediate Sirt1’s action on the melanocortin system and energy balance: roles for Sirt1 in neuronal firing and synaptic plasticity" 30 : 11815-11825, 2010
• 82 Min SW, "Acetylation of tau inhibits its degradation and contributes to tauopathy" 67 : 953-966, 2010
• 83 Matsuzaki H, "Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation" 102 : 11278-11283, 2005
• 84 Villalba JM, "A patent review of sirtuin activators: an update" 22 : 355-367, 2012
• 85 Gao J, "A novel pathway regulates memory and plasticity via SIRT1 and miR-134" 466 : 1105-1109, 2010
• 86 Selcher JC, "A necessity for MAP kinase activation in mammalian spatial learning" 6 : 478-490, 1999
• 87 Postina R, "A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model" 113 : 1456-1464, 2004